Changsha Central Hospital, Changsha, Hunan, China.
Beijing Innovation Alliance of TB Diagnosis and Treatment, Beijing, China.
BMC Infect Dis. 2018 Jun 7;18(1):261. doi: 10.1186/s12879-018-3169-7.
Limited treatment options of extensive drug-resistant tuberculosis (XDR-TB) have led to its high mortality worldwide. Relevant data about mortality of XDR-TB patients in literature are limited and likely underestimate the real situation in China, since the majority of patients with XDR-TB are lost to follow-up after discharge from TB hospitals. In this study, we sought to investigate the mortality and associated risk factors of Human Immunodeficiency Virus (HIV)-negative patients with XDR-TB in China.
All patients who were diagnosed with XDR-TB for the first time in four TB care centers across China between March 2013 and February 2015 were consecutively enrolled. Active tracking through contacting patients or family members by phone or home visit was conducted to obtain patients' survival information by February 2017. Multivariable Cox regression models were used to evaluate factors associated with mortality.
Among 67 patients enrolled, the mean age was 48.7 (Standard Deviation [SD] = 16.7) years, and 51 (76%) were men. Fourteen patients (21%) were treatment naïve at diagnosis indicating primary transmission. 58 (86.8%) patients remained positive for sputum smear or culture when discharged. During a median follow-up period of 32 months, 20 deaths occurred, with an overall mortality of 128 per 1000 person-years. Among patients who were dead, the median survival was 5.4 months (interquartile range [IQR]: 2.2-17.8). Seventeen (85%) of them died at home, among whom the median interval from discharge to death was 8.4 months (IQR: 2.0-18.2). In Cox proportional hazards regression models, body mass index (BMI) < 18.5 kg/m (adjusted hazard ratio [aHR] = 4.5, 95% confidence interval [CI]: 1.3-15.7), smoking (aHR = 4.7, 95%CI:1.7-13.2), or a clinically significant comorbidity including heart, lung, liver, or renal disorders or auto-immune diseases (aHR = 3.5, 95%CI: 1.3-9.4), were factors independently associated with increased mortality.
Our study suggested an alarming situation of XDR-TB patients in China with a sizable proportion of newly transmitted cases, a high mortality rate, and a long period in community. This observation calls for urgent actions to improve XDR-TB case management in China, including providing regimens with high chances of cure and palliative care, and enhanced infection control measures.
广泛耐药结核病(XDR-TB)的治疗选择有限,导致其在全球范围内死亡率较高。文献中关于 XDR-TB 患者死亡率的相关数据有限,并且可能低估了中国的实际情况,因为大多数 XDR-TB 患者在从结核病医院出院后就失去了随访。在这项研究中,我们旨在调查中国 HIV 阴性 XDR-TB 患者的死亡率及其相关危险因素。
2013 年 3 月至 2015 年 2 月期间,在中国的四个结核病防治中心连续纳入首次诊断为 XDR-TB 的所有患者。通过电话或家访主动联系患者或家属,截至 2017 年 2 月,以获得患者的生存信息。多变量 Cox 回归模型用于评估与死亡率相关的因素。
在纳入的 67 例患者中,平均年龄为 48.7(标准差[SD] = 16.7)岁,51 例(76%)为男性。14 例(21%)患者在诊断时为初次治疗,提示原发传播。58 例(86.8%)患者出院时痰涂片或培养仍为阳性。在中位随访 32 个月期间,20 例患者死亡,总死亡率为每 1000 人年 128 人。在死亡患者中,中位生存时间为 5.4 个月(四分位距[IQR]:2.2-17.8)。其中 17 例(85%)患者在家中死亡,从出院到死亡的中位间隔时间为 8.4 个月(IQR:2.0-18.2)。在 Cox 比例风险回归模型中,体重指数(BMI)<18.5kg/m2(调整后的危险比[aHR] = 4.5,95%置信区间[CI]:1.3-15.7)、吸烟(aHR = 4.7,95%CI:1.7-13.2)或存在临床显著合并症,包括心脏、肺部、肝脏或肾脏疾病或自身免疫性疾病(aHR = 3.5,95%CI:1.3-9.4)是与死亡率增加相关的独立因素。
我们的研究表明,中国 XDR-TB 患者的情况令人担忧,新发病例比例较大,死亡率较高,在社区中生存时间较长。这一观察结果呼吁中国采取紧急行动,改善 XDR-TB 病例管理,包括提供高治愈率和姑息治疗方案,以及加强感染控制措施。